The key goal was to identify acceptable analytical targets by analyzing human hepatocyte incubation samples with significant-resolution mass spectrometry (HRMS) and to confirm the outcomes in authentic urine specimens and to ascertain AB-FUBINACA's metabolic steadiness in human liver microsomes